3rd Quarter - Report

MUSCULAR DYSTROPHY ASSOCIATION, INC. for MUSCULAR DYSTROPHY ASSOCIATION, INC.

Firm
Client
Income
—
Expenses
$260,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

9 issue areas, each in the filer's own words, with who lobbied on it and where.

Aviation/Airlines/Airports AVI

Supported accessible air travel reforms to be included in the FAA Reauthorization Supported the MOBILE Act, legislation to make air travel more accessible Supported the Air Carrier Access Amendments Act, legislation to make air travel more accessible Supported the EVAC Act, legislation to ensure evacuations of airplanes considers those with disabilities Supported accessibility provisions within thenSecuring Growth and Robust Leadership in American Aviation Act of 2023 Supported the promulgation of the final Lavatories on Single-Aisle Airplanes rule. Advocated for stronger protections of individuals with disabilities when engaging with TSA

LobbyistCovered position, as disclosed
JOEL CARTNER —
MICHAEL KENNALLY LEWIS —
PAUL MELMEYER —

Contacted: Federal Aviation Administration (FAA); Transportation Security Administration (TSA); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; SENATE; Transportation, Dept of (DOT)

Budget/Appropriations BUD

Supported enhanced funding for NCATS Supported robust appropriations for the newborn screening program. Supported funding of ALS research, expanded access, and more

LobbyistCovered position, as disclosed
JOEL CARTNER —
MICHAEL KENNALLY LEWIS —
PAUL MELMEYER —

Contacted: Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA); Defense, Dept of (DOD); SENATE; Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Natl Institutes of Health (NIH)

Medical/Disease Research/Clinical Labs MED

Supported enhanced funding for NCATS Supported the nomination of Duchenne muscular dystrophy in front of HRSAs ACHDNC Worked on the introduction of the ALS Better Care Act Supported the introduction of legislation that increases access to genetic testing and genetic counselors Supported the Right Drug, Right Dose Act Supported robust appropriations for the newborn screening program. Supported funding of ALS research, expanded access, and more Advocated for the passage of the RARE ACT Supported the Medicare Orthotics & Prosthetics Patient-Centered Care Act Continued efforts to reintroduce the Newborn Screening Saves Lives Reauthorization Act Submitted comments to the FDA on decentralized clinical trial designs Supported the inclusion of certain provisions within the Pandemic and All-Hazards Preparedness Act reauthorization Endorsed the NIH Clinical Trial Diversity Act Provided comments to the FDA on the approach the Agency should take with neuromuscular disease treatments

LobbyistCovered position, as disclosed
JOEL CARTNER —
PAUL MELMEYER —

Contacted: Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); SENATE

Health Issues HCR

Advocated for the protection of the Medicaid program to the White House and Congress Supported enhanced funding for NCATS Supported the nomination of Duchenne muscular dystrophy in front of HRSAs ACHDNC Supported the Protecting Healthcare for All Patients Act Worked on the introduction of the ALS Better Care Act Supported the introduction of legislation that increases access to genetic testing and genetic counselors Supported the Right Drug, Right Dose Act Supported robust appropriations for the newborn screening program. Supported efforts to strengthen anti-discrimination provisions in rulemaking within healthcare settings Supported funding of ALS research, expanded access, and more Advocated for the passage of the RARE ACT Advocated for provisions addressing problems within the pharmacy benefit manager industry Urged CMS to tread carefully with the Medicaid unwinding Advocated for the elimination of junk plans to Congress and supported the Administrations proposal Endorsed the Telehealth Benefit Expansion for Workers Act Supported the Medicare Orthotics & Prosthetics Patient-Centered Care Act Continued efforts to reintroduce the Newborn Screening Saves Lives Reauthorization Act Supported the inclusion of certain provisions within the Pandemic and All-Hazards Preparedness Act reauthorization Submitted comments to the FDA on decentralized clinical trial designs Endorsed the NIH Clinical Trial Diversity Act Joined coalition comments on CMSs national coverage analysis evidence reviews and the emerging technology add-on payment program Provided comments to the Federal government on medical debt Provided comments to the FDA on the approach the Agency should take with neuromuscular disease treatments

LobbyistCovered position, as disclosed
JOEL CARTNER —
MICHAEL KENNALLY LEWIS —
PAUL MELMEYER —

Contacted: Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); SENATE; Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH); Labor, Dept of (DOL); Centers For Disease Control & Prevention (CDC)

Medicare/Medicaid MMM

Advocated for the protection of the Medicaid program to the White House and Congress Supported the Protecting Healthcare for All Patients Act Worked on the introduction of the ALS Better Care Act Supported the introduction of legislation that increases access to genetic testing and genetic counselors Supported the Right Drug, Right Dose Act Supported efforts to strengthen anti-discrimination provisions in rulemaking within healthcare settings Advocated for provisions addressing problems within the pharmacy benefit manager industry Urged CMS to tread carefully with the Medicaid unwinding Endorsed the Telehealth Benefit Expansion for Workers Act Supported the Medicare Orthotics & Prosthetics Patient-Centered Care Act Joined coalition comments on CMSs national coverage analysis evidence reviews and the emerging technology add-on payment program

LobbyistCovered position, as disclosed
JOEL CARTNER —
PAUL MELMEYER —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE

Insurance INS

Advocated for the protection of the Medicaid program to the White House and Congress Supported the Protecting Healthcare for All Patients Act Worked on the introduction of the ALS Better Care Act Supported the introduction of legislation that increases access to genetic testing and genetic counselors Supported the Right Drug, Right Dose Act Supported efforts to strengthen anti-discrimination provisions in rulemaking within healthcare settings Advocated for provisions addressing problems within the pharmacy benefit manager industry Urged CMS to tread carefully with the Medicaid unwinding Advocated for the elimination of junk plans to Congress and supported the Administrations proposal Endorsed the Telehealth Benefit Expansion for Workers Act Supported the Medicare Orthotics & Prosthetics Patient-Centered Care Act Joined coalition comments on CMSs national coverage analysis evidence reviews and the emerging technology add-on payment program Provided comments to the Federal government on medical debt

LobbyistCovered position, as disclosed
JOEL CARTNER —
PAUL MELMEYER —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; Centers For Medicare and Medicaid Services (CMS)

Pharmacy PHA

Supported the Protecting Healthcare for All Patients Act Worked on the introduction of the ALS Better Care Act Supported the introduction of legislation that increases access to genetic testing and genetic counselors Supported the Right Drug, Right Dose Act Supported efforts to strengthen anti-discrimination provisions in rulemaking within healthcare settings Supported funding of ALS research, expanded access, and more Advocated for provisions addressing problems within the pharmacy benefit manager industry Advocated for the elimination of junk plans to Congress and supported the Administrations proposal Supported the Medicare Orthotics & Prosthetics Patient-Centered Care Act Joined coalition comments on CMSs national coverage analysis evidence reviews and the emerging technology add-on payment program

LobbyistCovered position, as disclosed
JOEL CARTNER —
PAUL MELMEYER —

Contacted: Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; SENATE

Transportation TRA

Supported accessible air travel reforms to be included in the FAA Reauthorization Supported the MOBILE Act, legislation to make air travel more accessible Supported the Air Carrier Access Amendments Act, legislation to make air travel more accessible Supported the EVAC Act, legislation to ensure evacuations of airplanes considers those with disabilities Supported a final rule intended to make lavatories on single aisle aircrafts accessible.

LobbyistCovered position, as disclosed
JOEL CARTNER —
MICHAEL KENNALLY LEWIS —
PAUL MELMEYER —

Contacted: SENATE; Transportation, Dept of (DOT); Office of Management & Budget (OMB); Federal Aviation Administration (FAA); HOUSE OF REPRESENTATIVES

Education EDU

Provided comments on the Office of Special Education and Rehabilitative Services, Department of Educations notice of proposed rulemaking (NPRM) to amend the Individuals with Disabilities Education Act (IDEA) Part B regulations". Supported the RISE Act Supported the Full Funding is the Right IDEA Act

LobbyistCovered position, as disclosed
MICHAEL KENNALLY LEWIS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Education, Dept of

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.